Johnson & Johnson, a leader in immunology, has developed ARGES, a new AI-powered tool that could transform endoscopic ...
Bryan Johnson, the American entrepreneur renowned for his anti-ageing endeavours, has disclosed the details of his latest ...
The company announced on 18 February that the trial did not meet its primary endpoint measured by a depression rating scale, ...
Johnson & Johnson is normally a good buy for its dividend and the stability it offers. Over the past five years, however, the ...
Net product sales of CAPLYTA were $680.5 million for the full year 2024. This represents an increase of 47% compared to 2023.
An estimated 21 million American adults suffer from clinical depression. © 2025 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes ...
The U.S. has a much higher rate of maternal mortality than other high-income countries, and the risks are especially acute ...
Johnson & Johnson is well-diversified across thriving healthcare segments, with promising FDA approvals. Read why I assign a ...
The Food and Drug Administration approved Johnson & Johnson's nasal spray ... first-ever stand-alone therapy for treatment-resistant depression, which is when trying at least two standard ...